9th MASH Drug Development Summit

As part of a packed lineup of scientific meetings this season, Nordic Bioscience’s liver team is heading to the MASH Drug Development Summit, taking place September 24–26, 2025, in Boston, MA.

With the field of metabolic dysfunction-associated steatohepatitis (MASH) rapidly evolving, this summit offers a focused platform to engage in cutting-edge discussions on therapeutic advancements, trial design, and biomarker strategy. Nordic Bioscience will contribute to the conversation by highlighting the use of FIB-NIT™, a translational biomarker panel developed to monitor both fibrogenesis and fibrolysis in real time.

FIB-NIT™ enables dynamic tracking of liver fibrosis activity, supporting better-informed clinical decisions and improving the design and evaluation of antifibrotic therapies. It’s already playing a role in advancing MASH research by helping to stratify patients and assess treatment response non-invasively. Learn more about FIB-NIT™ here.

We look forward to connecting with fellow experts in liver disease research and continuing to advance biomarker-driven innovation.